By Fineline Cube 
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the Phase III GLORY-3 study of mazdutide, a dual glucagon (GCG) and glucagon-like peptide 1 receptor (GLP-1) receptor agonist. The trial will evaluate the efficacy and safety of mazdutide in Chinese adults with overweight or obesity comorbid with metabolic dysfunction-associated fatty liver disease (MAFLD).
Study Design
The multicenter, randomized, open-label Phase III study will compare mazdutide against semaglutide. Approximately 470 participants will be enrolled. The primary endpoints are the percentage change in liver fat content (LFC) as measured by magnetic resonance proton density fat fraction (MRI-PDFF) and the percentage change in body weight from baseline to week 48.
Previous Findings and Drug Development
A Phase II study previously demonstrated mazdutide’s significant advantages in weight control and liver fat reduction. Co-developed with Eli Lilly and Company (NYSE: LLY), mazdutide is currently awaiting regulatory approval in China for chronic weight management in adults with overweight or obesity and for glycemia control in adults with type 2 diabetes.-Fineline Info & Tech